IdentificationGeneric Name(1-Methyl-1h-Imidazol-2-Yl)-(3-Methyl-4-{3-[(Pyridin-3-Ylmethyl)-Amino]-Propoxy}-Benzofuran-2-Yl)-MethanoneDrugBank Accession NumberDB03062BackgroundNot AvailableTypeSmall MoleculeGroupsExperimentalStructure


3DDownload MOLSDF3D-SDFPDBSMILESInChI


 Similar StructuresStructure for (1-Methyl-1h-Imidazol-2-Yl)-(3-Methyl-4-{3-[(Pyridin-3-Ylmethyl)-Amino]-Propoxy}-Benzofuran-2-Yl)-Methanone (DB03062)× CloseWeightAverage: 404.4617 Monoisotopic: 404.184840654 Chemical FormulaC23H24N4O3SynonymsNot AvailablePharmacologyIndicationNot AvailableReduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, & validate predictive machine-learning models with structured datasets.See howContraindications & Blackbox WarningsAvoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Learn more  Avoid life-threatening adverse drug events & improve clinical decision support.Learn morePharmacodynamicsNot AvailableMechanism of actionTargetActionsOrganismUGlycylpeptide N-tetradecanoyltransferase 1Not AvailableHumansUGlycylpeptide N-tetradecanoyltransferaseNot AvailableYeastAbsorptionNot AvailableVolume of distributionNot AvailableProtein bindingNot AvailableMetabolismNot AvailableRoute of eliminationNot AvailableHalf-lifeNot AvailableClearanceNot AvailableAdverse EffectsImprove decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Learn more  Improve decision support & research outcomes with our structured adverse effects data.Learn moreToxicityNot AvailablePathwaysNot AvailablePharmacogenomic Effects/ADRs 


Not AvailableInteractionsDrug Interactions 


This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist. Not AvailableFood InteractionsNot AvailableCategoriesDrug CategoriesDietary Supplements
SupplementsChemical TaxonomyProvided by ClassyfireDescriptionThis compound belongs to the class of organic compounds known as benzofurans. These are organic compounds containing a benzene ring fused to a furan. Furan is a five-membered aromatic ring with four carbon atoms and one oxygen atom.KingdomOrganic compoundsSuper ClassOrganoheterocyclic compoundsClassBenzofuransSub ClassNot AvailableDirect ParentBenzofuransAlternative ParentsAryl ketones / Aralkylamines / Alkyl aryl ethers / Pyridines and derivatives / N-substituted imidazoles / Benzenoids / Heteroaromatic compounds / Furans / Oxacyclic compounds / Dialkylamines / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives


 show 4 moreSubstituentsAlkyl aryl ether / Amine / Aralkylamine / Aromatic heteropolycyclic compound / Aryl ketone / Azacycle / Azole / Benzenoid / Benzofuran / Ether / Furan / Heteroaromatic compound / Hydrocarbon derivative / Imidazole / Ketone / N-substituted imidazole / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Oxacycle / Pyridine / Secondary aliphatic amine / Secondary amine


 show 16 moreMolecular FrameworkAromatic heteropolycyclic compoundsExternal DescriptorsNot AvailableAffected organismsNot AvailableChemical IdentifiersUNIINot AvailableCAS numberNot AvailableInChI KeyVZBQJKIOAOUYJL-UHFFFAOYSA-NInChIInChI=1S/C23H24N4O3/c1-16-20-18(29-13-5-10-25-15-17-6-4-9-24-14-17)7-3-8-19(20)30-22(16)21(28)23-26-11-12-27(23)2/h3-4,6-9,11-12,14,25H,5,10,13,15H2,1-2H3IUPAC Name(3-{[3-methyl-2-(1-methyl-1H-imidazole-2-carbonyl)-1-benzofuran-4-yl]oxy}propyl)[(pyridin-3-yl)methyl]amineSMILESCN1C=CN=C1C(=O)C1=C(C)C2=C(O1)C=CC=C2OCCCNCC1=CN=CC=C1ReferencesGeneral ReferencesNot AvailableExternal LinksPubChem Compound446386PubChem Substance46505140ChemSpider393760BindingDB50121720ChEMBLCHEMBL355497ZINCZINC000003581083PDBe LigandR64PDB Entries1iylClinical TrialsClinical Trials 


PhaseStatusPurposeConditionsCountPharmacoeconomicsManufacturersNot AvailablePackagersNot AvailableDosage FormsNot AvailablePricesNot AvailablePatentsNot AvailablePropertiesStateSolidExperimental PropertiesNot AvailablePredicted PropertiesPropertyValueSourceWater Solubility0.0425 mg/mLALOGPSlogP2.83ALOGPSlogP2.55ChemaxonlogS-4ALOGPSpKa (Strongest Basic)8.79ChemaxonPhysiological Charge1ChemaxonHydrogen Acceptor Count5ChemaxonHydrogen Donor Count1ChemaxonPolar Surface Area82.18 Å2ChemaxonRotatable Bond Count9ChemaxonRefractivity114.23 m3·mol-1ChemaxonPolarizability44.88 Å3ChemaxonNumber of Rings4ChemaxonBioavailability1ChemaxonRule of FiveYesChemaxonGhose FilterYesChemaxonVeber's RuleNoChemaxonMDDR-like RuleYesChemaxonPredicted ADMET FeaturesPropertyValueProbabilityHuman Intestinal Absorption+1.0Blood Brain Barrier+0.9235Caco-2 permeable+0.6351P-glycoprotein substrateSubstrate0.8147P-glycoprotein inhibitor IInhibitor0.5912P-glycoprotein inhibitor IIInhibitor0.5211Renal organic cation transporterInhibitor0.5258CYP450 2C9 substrateNon-substrate0.8486CYP450 2D6 substrateNon-substrate0.5766CYP450 3A4 substrateSubstrate0.5884CYP450 1A2 substrateInhibitor0.7656CYP450 2C9 inhibitorNon-inhibitor0.8695CYP450 2D6 inhibitorNon-inhibitor0.6895CYP450 2C19 inhibitorNon-inhibitor0.9189CYP450 3A4 inhibitorInhibitor0.5CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5517Ames testNon AMES toxic0.6532CarcinogenicityNon-carcinogens0.9137BiodegradationNot ready biodegradable0.9811Rat acute toxicity2.4392 LD50, mol/kg Not applicablehERG inhibition (predictor I)Weak inhibitor0.5342hERG inhibition (predictor II)Inhibitor0.5371  ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397) SpectraMass Spec (NIST)Not AvailableSpectraSpectrumSpectrum TypeSplash KeyPredicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot AvailableTargetsBuild, predict & validate machine-learning modelsUse our structured and evidence-based datasets to unlock newinsights and accelerate drug research.Learn more  Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.Learn moreBinding Properties×PropertyMeasurementpHTemperature (°C)ReferencesIC 50 (nM)69N/AN/AA30097


 Details


 Binding Properties1. Glycylpeptide N-tetradecanoyltransferase 1KindProteinOrganismHumansPharmacological actionUnknownGeneral FunctionGlycylpeptide n-tetradecanoyltransferase activitySpecific FunctionAdds a myristoyl group to the N-terminal glycine residue of certain cellular and viral proteins.Gene NameNMT1Uniprot IDP30419Uniprot NameGlycylpeptide N-tetradecanoyltransferase 1Molecular Weight56805.865 DaReferencesBerman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article] 


 Details2. Glycylpeptide N-tetradecanoyltransferaseKindProteinOrganismYeastPharmacological actionUnknownGeneral FunctionGlycylpeptide n-tetradecanoyltransferase activitySpecific FunctionAdds a myristoyl group to the N-terminal glycine residue of certain cellular proteins. Substrate specificity requires an N-terminal glycine in the nascent polypeptide substrates. Ser is present at ...Gene NameNMT1Uniprot IDP30418Uniprot NameGlycylpeptide N-tetradecanoyltransferaseMolecular Weight51876.7 DaReferencesOverington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article] Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article] ×Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice. Learn more   Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52 